BGB-58067

DRUG3 trials

Sponsors

BeOne Medicines, Nader Sanai

Conditions

Advanced Solid TumorGlioblastoma (GBM)Healthy Volunteers

Early Phase 1

BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

RecruitingNCT07485049

Nader SanaiGlioblastoma (GBM)

Start: 2026-05-07End: 2028-11-01Target: 78Updated: 2026-05-14

Phase 1

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

RecruitingNCT06589596

BeOne MedicinesAdvanced Solid Tumor

Start: 2025-01-10End: 2027-09-30Target: 525Updated: 2026-05-22

A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants

Not yet recruitingNCT07590102

BeOne MedicinesHealthy Volunteers

Start: 2026-06-01End: 2026-09-30Target: 30Updated: 2026-05-15

Related Papers

Abstract CT193: Trial in progress: A first-in-human phase 1a/b study of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors and MTAP deficiency

Cancer Research2025-04-251 citations